147 related articles for article (PubMed ID: 23612378)
1. The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study.
Bonda-Shkedi E; Arush MW; Kaplinsky C; Ash S; Goshen Y; Yaniv I; Cohen IJ
J Pediatr Hematol Oncol; 2013 May; 35(4):271-5. PubMed ID: 23612378
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
[TBL] [Abstract][Full Text] [Related]
3. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
4. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
5. Acute transient cerebral toxicity associated with administration of high-dose methotrexate.
Mittal R; Mottl H; Nemec J
Med Princ Pract; 2005; 14(3):202-4. PubMed ID: 15863997
[TBL] [Abstract][Full Text] [Related]
6. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
7. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Review of Neuropsychologic Studies Supports the Concept That Adequate Folinic Acid Rescue Prevents Post Methotrexate Neurotoxicity.
Sadeh M; Toledano H; Cohen IJ
J Pediatr Hematol Oncol; 2023 Jan; 45(1):1-11. PubMed ID: 36598958
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Cohen IJ
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1057-1065. PubMed ID: 28455583
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Wippel B; Gundle KR; Dang T; Paxton J; Bubalo J; Stork L; Fu R; Ryan CW; Davis LE
Cancer Med; 2019 Jan; 8(1):111-116. PubMed ID: 30580500
[TBL] [Abstract][Full Text] [Related]
13. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
14. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
15. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
16. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
17. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
19. Anaphylactoid reaction to high-dose methotrexate and successful desensitization.
Oulego-Erroz I; Maneiro-Freire M; Bouzón-Alejandro M; Vázquez-Donsión M; Couselo JM
Pediatr Blood Cancer; 2010 Sep; 55(3):557-9. PubMed ID: 20533520
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
